Scroll peptide content on social media for ten minutes and you will encounter an almost endless catalog of compounds described as "clinically proven" or "used by doctors everywhere." The actual FDA-approved list is far shorter than that scroll suggests. It fits comfortably in a single table. Most of what influencers call peptide therapy sits in a completely different regulatory category, one with far weaker safety data and zero FDA oversight of the finished product. Understanding that gap is not a technicality. It determines whether you are taking a drug whose safety profile was tested in tens of thousands of people across multiple clinical trials, or an injectable compound that left a compounding pharmacy with no requirement to prove it works or that the dose on the label is accurate.
Summary / Quick Answer
FDA-approved peptide drugs are prescription medicines that cleared the agency's full New Drug Application (NDA) or Biologics License Application (BLA) review, meaning their safety and efficacy were established in large, controlled human trials. Roughly 100 peptide-based drugs carry that status; the most clinically relevant are listed in the table below.
- What's approved: Prescription peptides with an NDA or BLA on file at FDA, including GLP-1 receptor agonists, bone agents, reproductive hormones, and endocrine drugs covered in this article.
- What's compounded only: Peptides made by compounding pharmacies, legally permitted only for specific individual patients or during documented drug shortages, without the clinical trial package an NDA requires.
- What's research-stage: Compounds like BPC-157, CJC-1295, MK-677, and Selank, which are NOT FDA-approved as drugs or as dietary supplements. They have not cleared Phase 3 clinical trials and have no approved labeling.
- Decision shortcut: If a peptide requires a prescription from a licensed U.S. physician and is dispensed by a licensed U.S. pharmacy with a brand name and package insert, it is almost certainly in the approved category. If you are ordering it online from a "research chemicals" vendor, it is not.
What "FDA-Approved" Actually Means for a Peptide Drug
When the FDA approves a new drug, it is issuing a formal finding that the compound is safe and effective for a specific, defined indication at a specific dose and route of administration. That finding rests on a full NDA or BLA dossier, which typically includes years of animal toxicology data, pharmacokinetic studies, and at least two Phase 3 randomized controlled trials enrolling hundreds to thousands of patients.
The approved status belongs to a particular product, not to the molecule in the abstract. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg subcutaneous injection, NDA 209637) is approved for type 2 diabetes. Wegovy (semaglutide 2.4 mg subcutaneous injection, NDA 215256) is a separate approval for chronic weight management. Rybelsus (semaglutide oral tablet, NDA 213051) is a third approval for type 2 diabetes, this time for oral use. Same molecule, three distinct approvals covering different doses, routes, and indications.
This specificity matters because it means the safety data is tied to a precise formulation, a precise manufacturing process, and a precise clinical population. A compounded version of the same molecule carries none of that validation.
The FDA-Approved Peptide Drug List
The table below covers the peptide drugs most commonly discussed in wellness and clinical circles. It is not an exhaustive database of all ~100 approved peptides; it covers the compounds most relevant to the conversations consumers encounter.
| Generic name | Brand name(s) | First FDA approval | Indication | Route |
|---|---|---|---|---|
| Insulin (human recombinant) | Humulin R, Humulin N, Novolin, others | 1982 | Type 1 and type 2 diabetes mellitus | SC / IV |
| Synthetic oxytocin | Pitocin, generics | 1960s (modern NDA 018261) | Labor induction, postpartum hemorrhage | IV infusion / IM |
| Calcitonin-salmon (synthetic) | Miacalcin injection, Miacalcin nasal spray | 1975 | Postmenopausal osteoporosis, Paget's disease | SC / IM / intranasal |
| Leuprolide acetate | Lupron Depot, Eligard | 1985 | Prostate cancer, endometriosis, uterine fibroids, central precocious puberty | SC / IM (depot) |
| Octreotide acetate | Sandostatin, Sandostatin LAR | 1988 | Acromegaly, carcinoid syndrome, VIPoma | SC / IV / IM (LAR) |
| Glucagon | GlucaGen, Gvoke, Baqsimi | 2019 (modern NDA for Gvoke; original approval 1998 NDA 020928) | Severe hypoglycemia | SC / IM / intranasal |
| Liraglutide | Victoza (diabetes), Saxenda (obesity) | 2010 (Victoza); 2014 (Saxenda) | Type 2 diabetes; chronic weight management | SC |
| Teriparatide | Forteo, generics | 2002 | Osteoporosis at high fracture risk | SC |
| Dulaglutide | Trulicity | 2014 | Type 2 diabetes; CV risk reduction | SC |
| Semaglutide | Ozempic (diabetes SC), Rybelsus (diabetes oral), Wegovy (obesity/CV SC) | 2017 (Ozempic); 2021 (Wegovy); 2019 (Rybelsus) | Type 2 diabetes; chronic weight management; CV risk reduction | SC / oral |
| Vasopressin | Vasostrict, generics | 2014 (Vasostrict NDA; hospital vasopressin used much earlier) | Vasodilatory shock, intraoperative hypotension | IV |
| Abaloparatide | Tymlos | 2017 | Postmenopausal osteoporosis at high fracture risk | SC |
| Tirzepatide | Mounjaro (diabetes), Zepbound (obesity) | 2022 (Mounjaro); 2023 (Zepbound) | Type 2 diabetes; chronic weight management | SC |
| Bremelanotide | Vyleesi | 2019 | Hypoactive sexual desire disorder (premenopausal women) | SC (self-administered, on demand) |
Note on insulin: Animal-derived insulins predated the recombinant era, but 1982 marks the pivotal approval of Humulin, the first recombinant DNA-derived human insulin and the first product of any kind based on recombinant DNA technology to reach the U.S. market.
Note on tirzepatide: Tirzepatide is technically a dual GIP/GLP-1 receptor agonist, a peptide but not a pure GLP-1 class drug. It is included here because it is heavily discussed alongside semaglutide in weight-loss contexts.
Compounded Peptides: a Different Regulatory Category
Compounding pharmacies can legally prepare versions of FDA-approved drugs under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. During a documented drug shortage, 503B outsourcing facilities can compound at scale; 503A pharmacies can compound for individual patients. Neither track requires the pharmacy to submit the clinical trial data an NDA demands.
During the 2022-2025 semaglutide and tirzepatide shortages, compounding of these drugs was legally permitted because they appeared on the FDA's shortage list. Once the FDA declared the semaglutide shortage resolved, that legal basis evaporated for most compounders. The FDA also issued warnings during the shortage period about compounders using salt forms of semaglutide (semaglutide sodium, semaglutide acetate) that have not been shown to be safe or effective, and about serious adverse events tied to dosing errors in compounded versions.
The FDA maintains a separate list of "bulk drug substances that may present significant safety risks," which functions as a compounding restriction mechanism. Being on that list does not make a substance an approved drug. Being reviewed for the 503A bulks list, which is what BPC-157 was undergoing as of mid-2026, also does not make it an approved drug.
Compounds That Are NOT FDA-Approved Drugs
Several peptides are widely marketed in wellness and "biohacking" spaces with language that implies clinical legitimacy. A direct clarification on each:
BPC-157: Body Protection Compound-157 has no FDA approval as a drug or as a dietary supplement. Research exists in animal models for gut healing and tendon repair, but no large randomized controlled trial in humans has been completed. As of 2026, it is under review for the 503A compounding bulks list, which is an evaluation process, not an approval. A 2025 PMC review notes the absence of completed human Phase 3 data.
CJC-1295: This growth-hormone-releasing hormone analog is not FDA-approved as a drug or supplement. It appeared before the FDA's Pharmacy Compounding Advisory Committee in December 2024 for evaluation, meaning it is still being assessed for even compounding eligibility.
MK-677 (ibutamoren): This is a growth hormone secretagogue that acts on the ghrelin receptor. It is not FDA-approved. It is not a peptide in the strict structural sense, but it is heavily marketed in peptide communities. It has never completed a Phase 3 NDA-ready trial.
Selank and Semax: These are Russian-developed synthetic peptides. Neither has an FDA approval. Neither has completed a full NDA clinical trial program in the United States.
The honest framing is this: none of these compounds have cleared the evidentiary bar required for FDA approval, and all of them involve buying an injectable substance from an unregulated source and injecting it based on social media protocols.
How to Verify Whether a Peptide Is an FDA-Approved Version
Three practical checks take less than five minutes and apply to any peptide a provider has suggested or you have read about:
1. Search the FDA's Drugs@FDA database. Go to accessdata.fda.gov and search by drug name. An approved drug will show an NDA or BLA number, a sponsor, an approval date, and current labeling. If the search returns nothing, the drug is not approved under that name.
2. Check the DailyMed label. DailyMed at the National Library of Medicine carries the current FDA-approved prescribing information for all approved drugs. If the compound you are considering has no DailyMed entry, it does not have an approved label.
3. Confirm the dispensing pharmacy is licensed. Compounded versions of approved drugs (including GLP-1s, when legally permissible) should come from a state-licensed pharmacy or a registered 503B outsourcing facility, not a "research chemical" website. The FDA's 503B outsourcing facility list is publicly searchable.
If a peptide fails any of these three checks, you are dealing with something that has not been evaluated for the use being suggested. That is not a technicality. It is the entire safety question.
FAQ
Are GLP-1 peptides like semaglutide actually peptides?
Yes. Semaglutide, liraglutide, dulaglutide, and tirzepatide are all synthetic peptide analogs structurally related to human glucagon-like peptide-1, a 30-amino-acid gut hormone. They are among the most rigorously studied peptide drugs in history, with outcome trials enrolling tens of thousands of patients.
Does FDA approval mean a drug is risk-free?
No. Approval means the FDA judged that the documented benefits outweigh the documented risks for a specific population and indication. Every FDA-approved peptide drug has a known side-effect profile, contraindications, and drug interactions documented in its package insert. For the most complete picture of any specific drug's risks, the are peptides safe article covers the clinical evidence in detail, and the peptide side effects article breaks down the specific adverse events by drug class.
What about peptide supplements sold without a prescription?
Dietary supplements do not require FDA approval before sale. They also cannot legally make drug claims (treating a disease). A peptide marketed as a supplement with dosing instructions for therapeutic purposes exists in a legal grey zone. The FDA does not review supplement safety before products reach shelves, and most orally delivered peptides are broken down in digestion before reaching systemic circulation.
Can a doctor prescribe a peptide that is not FDA-approved?
In theory, physicians can prescribe drugs off-label, but they can only prescribe FDA-approved drugs off-label. Writing a prescription for BPC-157 or CJC-1295 is not the same as off-label prescribing of an approved drug, because there is no approved drug to prescribe. A compounding pharmacy may prepare these substances, but only if the compound is on the appropriate 503A or 503B list, which most of these peptides are not.
Conclusion: The Bottom Line on FDA-Approved Peptides
The honest list of FDA-approved peptide drugs is a short one, and it mostly contains names you recognize from pharmacy counters and hospital formularies: insulin, leuprolide, semaglutide, teriparatide, oxytocin, glucagon, and about a dozen others covered in the table above. Every one of them cleared at minimum two large Phase 3 randomized controlled trials before reaching patients. Every one has a published, FDA-reviewed prescribing information document that specifies the dose, the indication, and the known risks.
The peptides dominating online wellness culture, BPC-157, CJC-1295, MK-677, Selank, and similar compounds, share none of that. They have not been approved. They have not completed Phase 3 trials. They are often sold as "research chemicals" specifically to avoid FDA regulation of drugs.
That gap, between what influencers call peptide therapy and what the FDA has actually evaluated, is not a bureaucratic footnote. It is the entire question of whether there is any evidence that a compound is safe and effective at the dose and route you plan to use.
Next steps:
- Understand the full safety picture before considering any peptide: Are Peptides Safe? What the Research Actually Shows
- Get oriented on what peptides are and how they work in the body: What Are Peptides? A Plain-Language Guide
- Review the known adverse effects of FDA-approved peptide drugs by class: Peptide Side Effects: Evidence-Based Risks by Drug Type
This article is for informational purposes and not medical advice. Peptides, especially those marketed for therapeutic use, can interact with medications and health conditions. Consult a licensed physician before starting any supplement, particularly if you are pregnant, nursing, taking prescription medications, or managing a chronic condition.
This article is for informational purposes and not medical advice. Peptides, especially those marketed for therapeutic use, can interact with medications and health conditions. Consult a licensed physician before starting any supplement, particularly if you are pregnant, nursing, taking prescription medications, or managing a chronic condition.
